MAZEMaze Therapeutics, Inc.
Biological Products, (no Diagnostic Substances)
- Revenue
- —
- Operating margin
- —
- EBITDA
- −$140M
- 331% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$164M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear10% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2024 | FY2025 | YoY |
|---|---|---|---|
| Revenue | $168M | — | |
| Operating income | $58M | −$143M | 348% |
| Net income | $52M | −$131M | 351% |
| Operating cash flow | $76M | −$112M | 247% |
| Capex | $1M | $794K | 31% |
| Stock-based comp | $10M | $16M | 70% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $3M · 18
- Net
- −$3M
Pay vs performance
No pay-versus-performance disclosure yet.